The latest actions follow long-standing litigation in a New Jersey district court, where Arbutus alleges that the two pharmaceutical giants infringed upon five of its U.S. patents. While BioNTech acknowledged the new legal filings, the company declined to comment on its defense strategy. Pfizer did not provide an immediate response to inquiries regarding the suits.
In section Market Quotes
Arbutus Escalates Patent Battle Over Vaccine Lipid Technology
Arbutus Biopharma and its licensee Genevant have launched three new patent infringement lawsuits against Pfizer and BioNTech, targeting the lipid nanoparticle technology central to their Covid-19 vaccines. These filings in Canada and the Unified Patent Court mark a significant international expansion of the company’s ongoing legal campaign for compensation.
This aggressive legal posture coincides with a recent financial windfall for Arbutus. Earlier this month, the firm secured a $178 million settlement from Moderna to resolve separate patent disputes involving its own Covid-19 vaccine. Bolstered by this influx of capital, Arbutus intends to initiate a share repurchase program in the third quarter, earmarking up to $230 million for the buyback of its common stock.
Comments (0)
No comments yet. Be the first!